Industries > Pharma > Top 25 Biosimilar Drug Manufacturers 2019

Top 25 Biosimilar Drug Manufacturers 2019

Humira, Remicade, Enbrel, Aranesp, Rituxan, Sandoz, Teva, Hospira, Pfizer, STADA Arzneimittel, Mylan, 3SBio, Qilu Pharmaceutical, Shanghai Fosun Pharmaceutical, Biocon, Dr. Reddy’s Laboratories, Probiomed, Biosidus, Celltrion, LG Life Sciences, Other Companies

PUBLISHED: 17 April 2019
PAGES: 220
PRODUCT CODE: PHA0414
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0414 Categories: , Tags: , ,

Visiongain forecasts that the biosimilar drugs market will grow with a CAGR of 40% from 2018 to 2028. Growth is expected to be rapid during the first-half of the forecasted period due to the patent cliff from years 2012-2019, which will see the patent expiry of many of the most popular biologics in the world. The opening of the US market due to clearer defined guideline regarding biosimilars will lead to greater penetration of biosimilars in this lucrative market, which will help the rapid growth and development of the market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 220-page report you will receive 117 charts– all unavailable elsewhere.

The 220-page report provides clear detailed insight into the top 25 biosimilar drugs manufacturers. Discover the key drivers and challenges affecting the market.

Report Scope

• Discussion and overview of the leading biologic and biosimilar products, covering:
• Humira
• Remicade
• Enbrel
• Aranesp
• Rituxan
• Adalimumab biosimilars
• Infliximab biosimilars
• Etanercept biosimilars
• Darbepoetin Alpha biosimilars
• Rituximab biosimilars

• Profiles of leading biosimilar companies based in the US, Western Europe and Israel:
• Hospira
• Mylan
• Sandoz
• STADA Arzneimittel
• Teva Pharmaceutical Industries
• Other companies in these regions

• Profiles of leading biosimilar companies based in China:
• 3SBio
• Beijing ShuangLu Pharmaceuticals
• Qilu Pharmaceutical
• Shanghai Fosun Pharmaceuticals
• Tonghua Dongbao
• Other companies in China

• Profiles of leading biosimilar companies based in India:
• Biocon
• Dr. Reddy’s Laboratories
• Intas Biopharmaceuticals.
• Ranbaxy
• Reliance Life Sciences
• Wockhardt
• Zydus Cadila
• Other companies in China

• Profiles of leading biosimilar companies based in Latin America:
• Probiomed
• Biosidus
• Amega Biotech
• Other companies in Latin America

• Profiles of leading biosimilar companies based in the rest of the world:
• Celltrion
• LG Life Sciences
• Dong-A
• Bioton
• Biocad
• Other companies in the rest of the world

Top 25 Biosimilar Drug Manufacturers 2019

• The report provides information and discussion on:
• Company overview & analysis
• Biosimilars Products
• Future Outlook
• Technologies and activities
• R&D Pipelines

• Qualitative analysis: a SWOT and STEP analysis of the biosimilars market. Discussion on factors that drive and restrain the biosimilars market.

• Key questions answered by this report:
• What are its drivers and restraints of the biosimilar drugs market?
• What are the leading biosimilar products in the market and which companies manufacture them?
• Who are the leading biosimilars companies?
• What are their products, developmental candidates and therapeutic applications?
• What is the status of the clinical trials they are undergoing?
• What are the latest news and developments from those companies?
• What other biopharmaceutical companies seem promising within the regions we analyse, having potential to succeed in biosimilar drug development, production and marketing?
• What are leading companies’ biosimilar products and what candidates are in their R&D pipelines?
• What are the social, technological, economic and political forces affecting the world biosimilars market?

Visiongain’s study is intended for anyone requiring commercial analyses for the Top 25 Biosimilar Drugs Manufacturers 2019. You find data, trends and predictions.

Buy our report today Top 25 Biosimilar Drug Manufacturers 2019: Humira, Remicade, Enbrel, Aranesp, Rituxan, Sandoz, Teva, Hospira, Pfizer, STADA Arzneimittel, Mylan, 3SBio, Qilu Pharmaceutical, Shanghai Fosun Pharmaceutical, Biocon, Dr. Reddy’s Laboratories, Probiomed, Biosidus, Celltrion, LG Life Sciences, Other Companies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Top 25 Biosimilar Drug Manufacturers 2019


Download sample pages

Complete the form below to download your free sample pages for Top 25 Biosimilar Drug Manufacturers 2019


Latest Pharma news

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

READ

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

READ

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

READ

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

READ

Categories

Category